140 related articles for article (PubMed ID: 34627957)
1. Modulatory role of PACAP and VIP on HIFs expression in lung adenocarcinoma.
D'Amico AG; Maugeri G; Rasà DM; Reitano R; Saccone S; Federico C; Magro G; D'Agata V
Peptides; 2021 Dec; 146():170672. PubMed ID: 34627957
[TBL] [Abstract][Full Text] [Related]
2. PACAP and VIP regulate hypoxia-inducible factors in neuroblastoma cells exposed to hypoxia.
Maugeri G; D'Amico AG; Rasà DM; Saccone S; Federico C; Cavallaro S; D'Agata V
Neuropeptides; 2018 Jun; 69():84-91. PubMed ID: 29699729
[TBL] [Abstract][Full Text] [Related]
3. PACAP and VIP Inhibit HIF-1α-Mediated VEGF Expression in a Model of Diabetic Macular Edema.
Maugeri G; D'Amico AG; Saccone S; Federico C; Cavallaro S; D'Agata V
J Cell Physiol; 2017 May; 232(5):1209-1215. PubMed ID: 27661459
[TBL] [Abstract][Full Text] [Related]
4. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
5. PACAP and VIP Inhibit the Invasiveness of Glioblastoma Cells Exposed to Hypoxia through the Regulation of HIFs and EGFR Expression.
Maugeri G; D'Amico AG; Reitano R; Magro G; Cavallaro S; Salomone S; D'Agata V
Front Pharmacol; 2016; 7():139. PubMed ID: 27303300
[TBL] [Abstract][Full Text] [Related]
6. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
Moody TW; Zia F; Makheja A
Peptides; 1993; 14(2):241-6. PubMed ID: 8387187
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.
Harmar AJ; Fahrenkrug J; Gozes I; Laburthe M; May V; Pisegna JR; Vaudry D; Vaudry H; Waschek JA; Said SI
Br J Pharmacol; 2012 May; 166(1):4-17. PubMed ID: 22289055
[TBL] [Abstract][Full Text] [Related]
8. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
[TBL] [Abstract][Full Text] [Related]
9. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland.
Mazzocchi G; Malendowicz LK; Rebuffat P; Gottardo L; Nussdorfer GG
J Clin Endocrinol Metab; 2002 Jun; 87(6):2575-80. PubMed ID: 12050216
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Timely Top Med Cardiovasc Dis; 2005 Oct; 9():E33. PubMed ID: 16341283
[TBL] [Abstract][Full Text] [Related]
13. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) regulate murine neural progenitor cell survival, proliferation, and differentiation.
Scharf E; May V; Braas KM; Shutz KC; Mao-Draayer Y
J Mol Neurosci; 2008 Nov; 36(1-3):79-88. PubMed ID: 18629655
[TBL] [Abstract][Full Text] [Related]
16. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
17. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
[TBL] [Abstract][Full Text] [Related]
18. Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues.
Vertongen P; De Clerck P; Fournet JC; Martelli H; Hélardot P; Devalck C; Peeters T; Sariban E; Robberecht P
Neuropeptides; 1997 Oct; 31(5):409-13. PubMed ID: 9413016
[TBL] [Abstract][Full Text] [Related]
19. Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung.
Busto R; Carrero I; Guijarro LG; Solano RM; Zapatero J; Noguerales F; Prieto JC
Am J Physiol; 1999 Jul; 277(1):L42-8. PubMed ID: 10409229
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1alpha production and mRNA expression.
Pozo D; Guerrero JM; Calvo JR
Cytokine; 2002 Apr; 18(1):35-42. PubMed ID: 12090758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
